Startseite>>Signaling Pathways>> PROTAC>>TD-428

TD-428

Katalog-Nr.GC34319

TD-428 ist ein PROTAC, das durch Liganden fÜr Cereblon und BRD4 verbunden ist. TD-428 ist ein hochspezifischer BRD4-Abbaustoff mit einem DC50 von 0,32 nM. TD-428 ist ein BET-PROTAC, das TD-106 (einen CRBN-Liganden) umfasst, der an JQ1 (einen BET-Inhibitor) gebunden ist. TD-428 induziert effizient den BET-Proteinabbau.

Products are for research use only. Not for human use. We do not sell to patients.

TD-428 Chemische Struktur

Cas No.: 2334525-50-5

Größe Preis Lagerbestand Menge
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TD-428 is a highly specific BRD4 degrader with a DC50?of?0.32?nM[1].

TD-428, the BRD4 degrader with TD-106, is highly specific for BET proteins. TD-428 (0.01, 0.1, 1, 10, 100, 1000, and 10000 nM; 72?hours) inhibits the proliferation of 22RV1 cells with a CC50?of??20.1?nM[1].|| Cell Cytotoxicity Assay[1]|| Cell Line:|22RV1 cells|Concentration:|0.01, 0.1, 1, 10, 100, 1000, and 10000 nM|Incubation Time:|72?hours|Result:|Inhibited cell proliferation with a CC50?of?20.1?nM.|| Western Blot Analysis[1]||Cell Line:|U266 cells |Concentration:|1 nM, 10 nM, 100nM, 1000 nM, and 10?μM|Incubation Time:|12?hours|Result:|Induced the degradation of BET proteins.

[1]. Kim SA, et al. A novel cereblon modulator for targeted protein degradation. Eur J Med Chem. 2019 Mar 15;166:65-74.

Bewertungen

Review for TD-428

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TD-428

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.